中国天津新发Y群脑膜炎奈瑟菌的特征及疫苗诱导免疫原性研究
研究对天津一株侵袭性脑膜炎奈瑟菌Y群分离株(ST-18108)进行临床、分子及耐药特征分析,并在小鼠模型中比较MCV4与MPSV4的血清杀菌活性。MCV4第三剂后几何平均滴度294、血清阳转率100%,优于各MPSV4组;作者认为需更广菌株、更大样本及人体临床试验进一步验证。
要点
- 分离株为Y群ST-18108,仅对萘啶酸耐药,对7种药物保持敏感。
- MCV4第三剂后几何平均滴度294、血清阳转率100%,高于所有MPSV4组。
- MCV4组第二、三剂后抗体滴度显著高于MPSV4-A、MPSV4-B及对照组(P<0.05)。
核心结论
- 与MPSV4相比,MCV4在小鼠模型中针对Y群产生更强的杀菌抗体应答和更优保护性免疫,为脑膜炎球菌疫苗进一步研发奠定基础。
研究设计与样本
- 对一例侵袭性脑膜炎球菌病毒株进行流行病学调查和实验室检测,记录临床表现、分子特征及抗菌药物敏感性。
- 采用小鼠模型评估血清杀菌活性,50只小鼠随机分为五组,分别免疫MCV4、MPSV4-A、MPSV4-B、MPSV4-C或生理盐水。
- 每14天接种一次,共三剂,每剂免疫后14天采集血清进行血清杀菌活性分析。
主要发现
- 分离株 confirmed 为Y群,序列型为ST-18108。
- 对12种药物进行药敏试验,仅对萘啶酸耐药,对7种药物保持敏感。
- 血清杀菌活性试验中,MCV4诱导最强应答,第三剂后几何平均滴度为294,血清阳转率为100%,超过所有MPSV4组。
- MCV4组在第二剂和第三剂免疫后抗体滴度均显著高于MPSV4-A组、MPSV4-B组和对照组(P<0.05)。
- MCV4组内第二剂与第三剂之间滴度显著升高(P=0.004),而MPSV4各组未见显著升高(P>0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出后续研究应纳入更广泛的细菌菌株、更大的样本量,并最终开展人体临床试验以确认和扩展这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Since the incorporation of serogroups A and C meningococcal vaccines into China's national immunization program, the epidemiological profile of Neisseria meningitidis (Nm) has shifted toward serogroups not covered in routine vaccination, particularly Y and B. This study assessed the immunogenicity of the quadrivalent meningococcal polysaccharide vaccine (MPSV4) and the quadrivalent meningococcal polysaccharide conjugate vaccine (MCV4) against a newly identified serogroup Y strain in Tianjin, and characterized its clinical presentation, laboratory features, and antimicrobial resistance profile. METHODS: Epidemiological investigation and laboratory testing were undertaken to document the clinical manifestations, molecular characteristics, and antimicrobial susceptibility of the isolate. Serum bactericidal activity (SBA) was evaluated in a murine model. Fifty mice were randomized into five groups and immunized with MCV4, MPSV4-A, MPSV4-B, MPSV4-C, or normal saline. Vaccinations were administered at 14-day intervals for a total of three doses. Serum samples were collected 14 days after each immunization for SBA analysis. RESULTS: The bacterial isolate, obtained from a case of invasive meningococcal disease, was confirmed as serogroup Y and classified as sequence type ST-18108. Antimicrobial susceptibility testing against 12 agents revealed resistance solely to nalidixic acid, while susceptibility was retained to seven agents. In SBA assay, MCV4 induced the strongest response, with a geometric mean titer of 294 and a 100 % seroconversion rate after the third dose, exceeding responses observed in all MPSV4 groups. Antibody titers in the MCV4 cohort were significantly higher than those in the MPSV4-A, MPSV4-B, and control groups after both the second and third immunizations (P < 0.05). Furthermore, within the MCV4 group, titers rose significantly between the second and third doses (P = 0.004), whereas no significant increase was observed in MPSV4 groups (P > 0.05). CONCLUSIONS: Compared with MPSV4, MCV4 generated stronger bactericidal antibody responses and provided superior protective immunity against serogroup Y in a mouse model, which lays the groundwork for further development of meningococcal vaccines. Moving forward, studies should incorporate a broader range of bacterial strains, larger sample sizes, and ultimately human clinical trials to confirm and extend these findings.
引用
- Zhang G, Li W, Sui X, et al. Characterization and vaccine-induced immunogenicity of a re-emerging Neisseria meningitidis serogroup Y in Tianjin, China. Vaccine. 2025. PMID: 41456523. doi:10.1016/j.vaccine.2025.128156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。